ETR's third-quarter earnings beat the Zacks Consensus Estimate by 2.8%. However, its revenues miss the consensus estimate by 2%.

AES' third-quarter earnings beat the Zacks Consensus Estimate by 18.3%. However, its revenues miss the consensus estimate by 9.3%.

AMRN's third-quarter 2024 earnings meet estimates while revenues miss the same. Vascepa's sales in the United States decline year over year. Stock...

HII's Q3 revenues of $2.75 billion miss the Zacks Consensus Estimate by 4.5%. The top line also declines 2.4% year over year.

GGG's third-quarter 2024 sales decline 4% year over year due to lower demand in all its segments.

MIDD's third-quarter 2024 net sales decline 3.9% year over year on account of the lackluster performance of its segments.

A significant y/y decline in product sales due to softened demand within its target markets hurt NVEC's earnings in Q2.

CMPR's fiscal first-quarter organic constant-currency revenues increase 6% year over year, driven by growth across each of its businesses.

KNSL's Q3 results reflect continued execution of its strategy of disciplined underwriting and technology-enabled low costs.

ITGR's third-quarter results reflect solid Medical sales and margin expansion amid the divestiture of its Electrochem business.